<DOC>
	<DOCNO>NCT00094926</DOCNO>
	<brief_summary>The purpose study examine safety effectiveness long act injectable form atypical antipsychotic Risperidone ( Risperdal CONSTA ) , along treatment usual ( TAU ) , bipolar disorder patient 4 mood episode past year .</brief_summary>
	<brief_title>A Study Effectiveness Safety Risperdal CONSTA Added Usual Treatment Patients With Bipolar Disorder Who Have Frequent Mood Episodes .</brief_title>
	<detailed_description>Frequently-relapsing ( 4 episode last year ) bipolar patient sub-group patient multiple mood episode spite treatment . Currently available treatment may little impact number frequency manic and/or depress mood episode result , patient high average rate illness death . This study examine effectiveness side effect risperidone long-acting injection ( LAI ) add treatment usual ( TAU ) frequently-relapsing bipolar patient . The study two main phase . The first phase open-label ( patient doctor know medication dose patient receiving- risperidone LAI TAU ) last 16 week . During time , patient treat goal reach `` remission '' , predefined level improvement ( decrease number severity mood episode . ) Patients meet remission criterion end first phase randomize ( like flip coin ) either continue receive dose risperidone LAI plus TAU , placebo injection plus TAU . Patients continue second phase 52 week , time effectiveness measure time `` relapse '' ( worsen mood symptom severe enough require hospitalization major change medication . ) Additional effectiveness , safety , side effect measure evaluate throughout length study . Long-acting risperidone injection 25 mg administer every two week gluteal injection least one month . Thereafter , dose may increase 37.5mg 50 mg base clinical response tolerability . Supplemental use oral Risperdal ( 1 2 mg/day ) permit first 12 week Open-Label Stabilization Phase . Patients must take stable dose risperidone LAI 4 week immediately prior enter Double-Blind Phase .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Must provide inform consent Must agree receive regular injection Must current diagnosis bipolar disorder I II Must least four episode mood disorder last year require psychiatric intervention Female may pregnant breastfeeding , least 1 year postmenopausal , use reliable adequate birth control Psychiatric diagnosis due directly effect substance general medical condition Substance dependence Received treatment longacting injectable antipsychotic less 2 injection cycle prior baseline ( , example , drug inject every 2 week , patient could enroll study receive injection within last 4 week ) Received Electroconvulsive Therapy ( ECT ) within last month Began psychotherapy ( `` talk therapy '' ) within 2 month In past month treat medication : carbamazepine , oxcarbazepine , fluoxetine , paroxetine , clozapine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Risperidal CONSTA</keyword>
	<keyword>Bipolar disorder</keyword>
	<keyword>mood episode</keyword>
	<keyword>Safety efficacy , adjuvant therapy</keyword>
</DOC>